The Vertex Pharmaceuticals story
What drives Vertex Pharmaceuticals, what its price assumes and what could change the story, written from its own filings.
- CF still dominates. TRIKAFTA contributed 75% of revenue in the quarter to June 2026, while ALYFTREK is becoming its successor within the same patient population.
- Diversification is gaining traction. CASGEVY revenue reached $76 million and JOURNAVX revenue reached $50 million in the quarter to June 2026, while povetacicept has an FDA decision date of November 30, 2026.
- Expansion draws on cash. The approximately $10.0 billion Crinetics agreement follows a June 30, 2026 balance of $13.6 billion in cash, cash equivalents and total marketable securities.
